Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.77 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.77 |
| ▸ | PNMT | P11086 | 5/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CD44 | P16070 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850369 | 1.00 | CHRNB2 (0.77) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Hydrochloric Acid SCHEMBL15238605 | 0.98 | CHRNB2 (0.74) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Hydrochloric Acid SCHEMBL4790441 | 0.98 | CHRNB2 (0.74) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL30183351 | 0.92 | CHRNB2 (0.77) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL2565015 | 0.92 | CHRNB2 (0.77) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Hydrochloric Acid SCHEMBL785959 | 0.90 | CHRNB2 (0.74) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Hydrochloric Acid SCHEMBL29759853 | 0.90 | CHRNB2 (0.74) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL19194504 | 0.88 | SIGMAR1 (0.61) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL19200207 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Trifluoroacetic Acid SCHEMBL30343298 | 0.84 | CHRNB2 (0.56) | CHRNB2CHRNA4PNMTSIGMAR1CD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658655-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | claimed |
| US-20250353858-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | claimed |
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2024160278-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | claimed |
| EP-4408842-A1 | BICYCLIC AMINE DERIVATIVES AS GABAA a5 RECEPTOR MODULATORS | Richter Gedeon Nyrt. (HU) | 2024-08-07 | — | — | EP | claimed |
| WO-2023053015-A1 | BICYCLIC AMINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2023-04-06 | — | — | WO | claimed |
| EP-4126859-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-C]PYRIDAZINE DERIVATIVES AS GABAA ALPHA5 RECEPTOR MODULATORS | Richter Gedeon Nyrt. (HU) | 2023-02-08 | — | — | EP | claimed |
| WO-2021191838-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2021-09-30 | — | — | WO | claimed |
| EP-3717488-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | Dart NeuroScience, LLC (US) | 2020-10-07 | — | — | EP | claimed |
| CN-111655695-A | Substituted furopyrimidines as PDE1 inhibitors | 达特神经科学有限公司 | 2020-09-11 | — | — | CN | claimed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | claimed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | claimed |
| US-6476226-B2 | PLATELET GLYCOPROTEIN IIB/IIIA FIBRINOGEN; ANTICOAGULANTS; THROMBOLYTIC AGENTS; THROMBOEMBOLIC DISORDERS; ANTIINFLAMMATORY AGENTS; BONE DISORDERS; ANTITUMOR, -METASTASIS, -ARTHRITIC AGENTS; ASTHMA; PSORIASIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-05 | — | — | US | claimed |
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-18 | — | — | US | claimed |
| US-6303609-B1 | USED FOR THE INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-10-16 | — | — | US | claimed |
| EP-1131306-A2 | ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-09-12 | — | — | EP | claimed |
| WO-2000029406-A2 | NOVEL ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-05-25 | — | — | WO | claimed |
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-1989005643-A1 | HETEROCYCLIC-SUBSTITUTED QUINOLINE-CARBOXYLIC ACIDS | PFIZER INC. (US) | 1989-06-29 | — | — | WO | disclosed |
| EP-0321191-A2 | Heterocyclic-substituted quinoline-carboxylic acids | PFIZER INC. (US) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353858-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKK, DGKA | CHRNB2 4235/4885CHRNA4 4388/4885PNMT 2786/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | CHRNB2 1490/4885CHRNA4 1721/4885PNMT 4553/4885 |
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | F13B, F11, FGB | CHRNB2 1795/4885CHRNA4 1227/4885PNMT 4807/4885 |
| US-20100130495-A1 | COMPOUNDS 563 | BACE1, PSEN1, PSEN2 | CHRNB2 43/4885CHRNA4 85/4885PNMT 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.